$MVIS
MICROVISION, INC. Stock $mvis

$mvis Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224030625 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$190.0K	$1.900M
YoY Change	-81.85%	477.51%
Cost Of Revenue	$583.0K	$1.554M
YoY Change	-6.72%	121.68%
Gross Profit	-$393.0K	$346.0K
YoY Change	-193.13%	-193.01%
Gross Profit Margin	-206.84%	18.21%
Selling, General & Admin	$6.599M	$7.746M
YoY Change	-24.52%	-20.08%
% of Gross Profit		2238.73%
Research & Development	$8.736M	$14.20M
YoY Change	-43.94%	2.55%
% of Gross Profit		4105.2%
Depreciation & Amortization	$600.0K	$600.0K
YoY Change	-45.45%	25.26%
% of Gross Profit		173.41%
Operating Expenses	$15.31M	$24.98M
YoY Change	-37.03%	6.16%
Operating Profit	-$15.71M	-$24.63M
YoY Change	-34.27%	3.06%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$297.0K	$785.0K
YoY Change	-53.38%	-78.01%
Pretax Income	-$15.41M	-$23.85M
YoY Change	-33.75%	17.29%
Income Tax	$108.0K	$84.00K
% Of Pretax Income
Net Earnings	-$15.52M	-$23.93M
YoY Change	-33.88%	16.11%
Net Earnings / Revenue	-8166.84%	-1259.47%
Basic Earnings Per Share	-$0.07	-$0.11
Diluted Earnings Per Share	-$0.07	-$0.11
COMMON SHARES
Basic Shares Outstanding	212.8M shares	206.7M shares
Diluted Shares Outstanding	213.0M shares	208.7M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.20M	$56.68M
YoY Change	-44.67%	-39.61%
Cash & Equivalents	$16.52M	$26.75M
Short-Term Investments	$26.68M	$29.93M
Other Short-Term Assets	$4.857M	$3.646M
YoY Change	-15.75%	56.35%
Inventory	$4.486M	$4.203M
Prepaid Expenses
Receivables	$232.0K	$1.970M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$53.05M	$66.57M
YoY Change	-41.98%	-35.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.668M	$8.131M
YoY Change	-18.95%	-18.27%
Goodwill
YoY Change
Intangibles	$12.56M	$13.08M
YoY Change	-29.29%	-28.6%
Long-Term Investments
YoY Change
Other Assets	$2.894M	$3.282M
YoY Change	-5.76%	22.1%
Total Long-Term Assets	$35.22M	$36.84M
YoY Change	-20.9%	-18.81%
TOTAL ASSETS
Total Short-Term Assets	$53.05M	$66.57M
Total Long-Term Assets	$35.22M	$36.84M
Total Assets	$88.26M	$103.4M
YoY Change	-35.08%	-30.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.487M	$1.448M
YoY Change	-35.18%	-23.39%
Accrued Expenses	$5.893M	$8.894M
YoY Change	-18.2%	34.86%
Deferred Revenue	$180.0K	$172.0K
YoY Change	-96.37%	-97.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.61M	$12.65M
YoY Change	-55.91%	-44.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$134.0K	$120.0K
YoY Change	-77.55%	48.15%
Total Long-Term Liabilities	$134.0K	$120.0K
YoY Change	-77.55%	48.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.61M	$12.65M
Total Long-Term Liabilities	$134.0K	$120.0K
Total Liabilities	$22.41M	$24.71M
YoY Change	-40.55%	-31.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$831.1M	-$815.6M
YoY Change	11.47%	12.94%
Common Stock	$213.0K	$212.0K
YoY Change	12.11%	12.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.86M	$78.71M
YoY Change
Total Liabilities & Shareholders Equity	$88.26M	$103.4M
YoY Change	-35.08%	-30.43%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$15.52M	-$23.93M
YoY Change	-33.88%	16.11%
Depreciation, Depletion And Amortization	$600.0K	$600.0K
YoY Change	-45.45%	25.26%
Cash From Operating Activities	-$14.09M	-$18.63M
YoY Change	-30.9%	11.97%
INVESTING ACTIVITIES
Capital Expenditures	-$9.000K	$166.0K
YoY Change	-101.8%	-80.9%
Acquisitions
YoY Change
Other Investing Activities	$3.574M	-$3.965M
YoY Change	11.83%	-129.82%
Cash From Investing Activities	$3.583M	-$4.131M
YoY Change	32.46%	-133.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-16.00K	5.153M
YoY Change	-100.34%	-88.11%
NET CHANGE
Cash From Operating Activities	-14.09M	-18.63M
Cash From Investing Activities	3.583M	-4.131M
Cash From Financing Activities	-16.00K	5.153M
Net Change In Cash	-10.52M	-17.61M
YoY Change	-18.7%	-145.02%
FREE CASH FLOW
Cash From Operating Activities	-$14.09M	-$18.63M
Capital Expenditures	-$9.000K	$166.0K
Free Cash Flow	-$14.08M	-$18.80M
YoY Change	-32.6%	7.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	MVIS	Total Finance Lease Expense TotalFinanceLeaseExpense	12000	usd
	us-gaap	Lease Cost LeaseCost	1333000	usd
	us-gaap	Lease Cost LeaseCost	1294000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1299000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1096000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12348000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13758000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2113000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2323000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11936000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12714000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	14049000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15037000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046	pure
CY2024Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent		usd
	MVIS	Impairment Of Operating Lease Rightofuse Assets ImpairmentOfOperatingLeaseRightofuseAssets		usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1		usd
	MVIS	Issuance Of Common Stock For Subscriptions Receivable IssuanceOfCommonStockForSubscriptionsReceivable		usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger		usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss		usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger		usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss		usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	MVIS	Total Finance Lease Expense TotalFinanceLeaseExpense		usd
	MVIS	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases		usd
	MVIS	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3027000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-23930000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-56000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	78709000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	89741000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6427000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	168000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55686000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39636000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	119000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	112505000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	95804000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	95804000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7096000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26099000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-50243000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-109000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-109000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	78709000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-50243000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39636000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3570000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4151000	usd
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	1706000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	15000	usd
	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	-3027000	usd
	MVIS	Impairment Of Operating Lease Rightofuse Assets ImpairmentOfOperatingLeaseRightofuseAssets	-393000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	48000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	56000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7096000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6815000	usd
	MVIS	Net Accretion Of Premium On Shortterm Investments NetAccretionOfPremiumOnShorttermInvestments	-535000	usd
	MVIS	Net Accretion Of Premium On Shortterm Investments NetAccretionOfPremiumOnShorttermInvestments	-695000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1021000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	821000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	410000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-69000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1818000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	31000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-850000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	246000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	254000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4138000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-765000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1692000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1299000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1096000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-476000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	81000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39393000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30124000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	22655000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	48700000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23488000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17302000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6300000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11233000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	280000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1484000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7413000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18681000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	62000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	168000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26109000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	55866000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26171000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56021000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations	-20609000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations	44578000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49391000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21954000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28782000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66532000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	167000	usd
	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	3263000	usd
	MVIS	Accrued Financing Fees AccruedFinancingFees	10000	usd
	MVIS	Accrued Financing Fees AccruedFinancingFees	180000	usd
	MVIS	Issuance Of Common Stock For Subscriptions Receivable IssuanceOfCommonStockForSubscriptionsReceivable	925000	usd
	MVIS	Non Cash Foreign Currency Translation Adjustments NonCashForeignCurrencyTranslationAdjustments	-64000	usd
	MVIS	Non Cash Foreign Currency Translation Adjustments NonCashForeignCurrencyTranslationAdjustments	24000	usd
	MVIS	Unrealized Gain Loss On Investment Securities Available For Sale UnrealizedGainLossOnInvestmentSecuritiesAvailableForSale	-45000	usd
	MVIS	Unrealized Gain Loss On Investment Securities Available For Sale UnrealizedGainLossOnInvestmentSecuritiesAvailableForSale	95000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26748000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62308000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	73000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	3263000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	1961000	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	961000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28782000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66532000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56700000	usd
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	26800000	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	29900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zftThlvYsNob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0nqpkPR6Fgc">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts therein. The most significant estimates and assumptions relate to business combinations, valuation of intangibles, revenue recognition, inventory valuation, valuation of share-based payments, income taxes, depreciable lives assessment and related disclosure of contingent assets and liabilities. Due to the inherent uncertainty involved, actual results reported in future periods could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zTSPyLBRSeR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z1X2Ho8fkhA8">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to a concentration of credit risk are primarily cash, cash equivalents, and investment securities. As of June 30, 2024, cash and cash equivalents are comprised of operating checking accounts and short-term highly rated money market savings accounts. Short-term investments are comprised of highly rated corporate bonds and U.S. Treasury securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended June 30, 2024, two customers accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zTzyKLRDmX45" title="Concentration risk, percentage">71</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIakyVnEsTUh" title="Concentration risk, percentage">11</span>% of total revenue, respectively. For the same period in 2023, four customers accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkJ0mFVua4P8" title="Concentration risk, percentage">20</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgRCqWk9Gobk" title="Concentration risk, percentage">20</span>%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4NostZbfgD1" title="Concentration risk, percentage">17</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpUNiHPNlqth" title="Concentration risk, percentage">16</span>% of total revenue, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2024, two customers accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2CTEWRqCwu6" title="Concentration risk, percentage">58</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zu2UnUsQWLP7" title="Concentration risk, percentage">22</span>% of total revenue, respectively. For the same period in 2023, three customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zTpndaTCOvEl" title="Concentration risk, percentage">33</span>%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwXeeG966NEa" title="Concentration risk, percentage">22</span>%, and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8S4ejpqDyp1" title="Concentration risk, percentage">11</span>% of total revenue, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, accounts receivable related to these customers accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9kcoY4PJyOf" title="Concentration risk, percentage">80</span>% of total accounts receivable, net of allowances on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Typically, a significant concentration of components and the products sold are manufactured and obtained from single or limited-source suppliers. The loss of any single or limited-source supplier, the failure of any of these suppliers to perform as expected, or the disruption in the supply chain of components from these suppliers could subject the Company to risks and uncertainties including, but not limited to, increased cost of sales, possible loss of revenues, or significant delays in product development or product deliveries, any of which could adversely affect the Company’s financial condition and operating results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-23930000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-20609000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	208665000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	208665000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	177302000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177302000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202706000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202706000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	176009000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	176009000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2700000
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3000000.0	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1900000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2856000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	329000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1111000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1970000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	949000	usd
	MVIS	Change In Contract Assets And Accounts Receivable ChangeInContractAssetsAndAccountsReceivable	1021000	usd
	MVIS	Percentage Change In Contract Assets And Accounts Receivable PercentageChangeInContractAssetsAndAccountsReceivable	1.076	pure
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	172000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	300000	usd
	MVIS	Contract With Customer Liability Current Change ContractWithCustomerLiabilityCurrentChange	128000	usd
	MVIS	Contract With Customer Liability Current Percent Change ContractWithCustomerLiabilityCurrentPercentChange	-0.427	pure
CY2024Q2	MVIS	Contract With Customer Assetand Liabilities Net ContractWithCustomerAssetandLiabilitiesNet	1798000	usd
CY2023Q4	MVIS	Contract With Customer Assetand Liabilities Net ContractWithCustomerAssetandLiabilitiesNet	649000	usd
	MVIS	Contract With Customer Assetand Liabilities Net Change ContractWithCustomerAssetandLiabilitiesNetChange	1149000	usd
	MVIS	Contract With Customer Assetand Liabilities Net Percent Change ContractWithCustomerAssetandLiabilitiesNetPercentChange	1.770	pure
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	usd
CY2024Q2	MVIS	Revenue Recognized Percentage RevenueRecognizedPercentage	1	pure
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	29952000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29934000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	28585000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	29952000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29934000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	29952000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29934000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	28585000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	28585000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28611000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	21350000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	19000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	21350000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	19000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2974000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	2974000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1000	usd
CY2024Q2	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	1000000.0	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1995000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1574000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	305000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2208000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1995000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	4203000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3874000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27648000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27499000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19517000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18467000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8131000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9032000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	600000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Depreciation Depreciation	1100000	usd
	us-gaap	Depreciation Depreciation	1700000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20198000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4090000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3027000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13081000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20198000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2963000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17235000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
	MVIS	Impairment Of Fair Value ImpairmentOfFairValue	4500000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3000000.0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1400000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	968000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1501000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1471000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	829000	usd
CY2024Q2	MVIS	Finite Lived Intangible Assets Amortization Expense After Year Three FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree	8312000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13081000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7096000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6815000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	668000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.42
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	108000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	668000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.42
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	108000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	9983000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	6089000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	2786000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	823000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.71
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	12463000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.85
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	800000	usd
	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	Finance leases contain options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless the Company is reasonably certain to exercise the purchase option.
CY2021Q3	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	3000000.0	usd
CY2022Q2	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	expiration of November 2027.
CY2022Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	200000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	expiration from April 2027 to April 2025
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	100000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	668000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	592000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1333000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1282000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	12000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1110000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2017000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1979000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1950000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	5700000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-030625-index-headers.html	Edgar Link	pending
0001493152-24-030625-index.html	Edgar Link	pending
0001493152-24-030625.txt	Edgar Link	pending
0001493152-24-030625-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mvis-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
mvis-20240630_cal.xml	Edgar Link	unprocessable
mvis-20240630_def.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mvis-20240630_lab.xml	Edgar Link	unprocessable
mvis-20240630_pre.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MVIS
MICROVISION, INC. Stock $mvis

2024 Q3 Form 10-Q Financial Statement

#000149315224030625 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MVIS MICROVISION, INC. Stock $mvis

2024 Q3 Form 10-Q Financial Statement

#000149315224030625 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MVIS
MICROVISION, INC. Stock $mvis